As i am aware it has allways been the plan to execute a deal for MPS first and has been mentioned to have the data for both treatments prior to maximise value for MPS which they now have due next week.
The deal for OA either regional China etc will come after which also has been mentioned and I wouldn't think any company from a business prospective would deal with us until we have the greenlight from the FDA in regards to dosing etc.
I believe it will be a pivotal moment for us if we get the nod,our data is simply to good to ignore.
As for management they have got us to where we are, knocking on the door of something that could well be a game changer albeit with mistakes along the way.
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-116
-
- There are more pages in this discussion • 121 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.0¢ |
Change
-0.010(5.00%) |
Mkt cap ! $66.54M | |||
| Open | High | Low | Value | Volume |
| 20.0¢ | 21.0¢ | 19.0¢ | $203.4K | 1.019M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 387930 | 19.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.5¢ | 65468 | 2 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| PAR (ASX) Chart |